RAP 0.00% 20.5¢ resapp health limited

RAP media thread., page-14

  1. 26,439 Posts.
    lightbulb Created with Sketch. 1717
    I can't see why eHealth and hospital/ER industries and humanitarian organisation wouldn't want a product like this as it's quick and accurate diagnosis saving them a bundle on resources and additional (X-ray/blood sample) cost and insurance cost.

    I can see initial resistance from GP as they make a bucket load from respiratory disease diagnosis with their 30 minute consultation (excluding blood sample and X-ray) reduced to only 10-15 minutes but it does mean if they use ResAppDx, they will be able to see more patients in that time frame and more importantly less stress on them trying to diagnosis it correctly given it's so difficult using X-ray and blood sample let alone with just the stethoscope....and more importantly less insurance cost.
 
watchlist Created with Sketch. Add RAP (ASX) to my watchlist

Currently unlisted public company.

arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.